abrdn Life Sciences Investors 

Tekla Life Sciences Investors operates as a closed-end investment fund or Investment trust. The firm engages in the investment in the life sciences industry. It invests in biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals and healthcare information technology and services. The company was founded on February 20, 1992 and is headquartered in Boston, MA.

abrdn Healthcare Investors operates as a closed-end investment fund, which engages in the investment in the life sciences industry. It invests in biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals and healthcare information technology and services. The company was founded on February 20, 1992 and is headquartered in Boston, MA.

HQL pays quarterly dividends. Even during the pandemic, its performance has been better than its peers. Current prices look attractive.

Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend

Liberty All-Star Growth Fund

Bancroft Fund Ltd

BlackRock Virginia Municipal Bond Trust

Boulder Growth & Income Fund

Blackrock Long-Term Municipal Advantage Trust

Virtus AllianzGI Convertible & Income 2024 Target Term Fund

Eaton Vance California Municipal Income Trust

MFS Intermediate High Income Fund

Cornerstone Strategic Value Fund Inc

Cornerstone Total Return Fund Inc

MFS High Income Municipal Trust

MFS Investment Grade Municipal Trust

BNY Mellon High Yield Strategies Fund 

Eaton Vance Risk-Managed Diversified Equity Income Fund

Eaton Vance

Eaton Vance Short Duration Diversified Income Fund

Eaton Vance California Municipal Bond Fund

Franklin Limited Duration Income Trust

Gabelli Equity Trust

Templeton Global Income Fund

Eagle Capital Growth Fund Inc

abrdn Healthcare Investors 

John Hancock Tax-Advantaged Global Shareholder Yield Fund

John Hancock Investors Trust

4 out of 24 CEF sectors positive on price and 2 out of 24 sectors positive on NAV last week. Date for PIMCO merger of PCI and PKO into PDI announced.

Weekly Closed-End Fund Roundup: November 28, 2021

Tekla Life Sciences Investors mainly invests in Biotechnology firms.

Tekla Life Sciences Investors Rides Biotechnology Wave, Offers Growth With Steady Income

India Fund Inc

Franklin Templeton Dragon Fund

Double-digit dividends are rare. A sky-high yield of 27.2% is an outright income unicorn.

5 Dividend Funds Yielding Up To 27.2%

As an income investor, the 7.8% yield is quite attractive to me if HQL can support it. I continue my series on CEFs looking beyond the yield.

Evaluating Closed-End Funds: HQL Is Another Fine Pick In A Hot Sector

Annovis Bio

Arvinas Inc

Anavex Life Sciences

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Biohaven Pharmaceutical Hld

Biogen

Loncar Cancer Immunotherapy ETF

Denali Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

iShares Nasdaq Biotechnology ETF

Defiance Nasdaq Junior Biotechnology ETF

INmune Bio Inc

Intra-Cellular Therapies

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Eli Lilly

Invesco Dynamic Biotechnology & Genome ETF

Prothena

Cassava Sciences Inc

Supernus Pharmaceuticals

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

BOSTON--(BUSINESS WIRE)--On May 18, 2021, Tekla Life Sciences Investors declared a stock distribution of $0.41 per share. The record date for the stock distribution is May 28, 2021 and the payable date is June 30, 2021. The Fund will trade ex-distribution on May 27, 2021. This stock distribution will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder. The shares will be valued at the lower of the net asset value or market price on the pricing

Tekla Life Sciences Investors Declares Stock Distribution

abrdn World Healthcare Fund 

Healthcare offers essential services that people can't go without, recession or not. The Tekla funds can offer potential in any one of their funds for healthcare exposure.

Tekla Funds: In A World That Needs Healthcare, These Funds Have A Place In A Portfolio

Principal Healthcare Innovators Index ETF

Direxion Daily Healthcare Bull 3x Shares

Fidelity MSCI Health Care ETF

First Trust Nasdaq Pharmaceuticals ETF 

First Trust Health Care AlphaDEX Fund

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare ETF

John Hancock Multifactor Healthcare ETF

Global X Longevity Thematic ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

ProShares UltraShort Health Care

ProShares Ultra Health Care

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

Pacer BioThreat ETF

SPDR S&P Pharmaceuticals ETF

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.

Biotech Innovations Remain At Forefront

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those aged 65 years and older.

Moving Beyond COVID In Biopharma

HQL has outperformed other healthcare-oriented CEFs over the past year. It's selling at a -7.27% discount to NAV.

Tekla Life Sciences Investors: 8% Yield, 7% Discount

BOSTON--(BUSINESS WIRE)--On December 21, 2020, Tekla Life Sciences Investors declared a special cash distribution of $0.02 per share in order to satisfy annual tax distribution requirements. The record date for the distribution is December 31, 2020 and the payable date is January 6, 2021. The Fund will trade ex-distribution on December 30, 2020. This distribution will be paid in cash and will be taxable to shareholders in 2020. Tekla Life Sciences Investors (NYSE: HQL) is a closed-end fund that

Tekla Life Sciences Investors Declares Cash Distribution

BlackRock Taxable Municipal Bond Trust

Blackrock Core Bond Trust

BlackRock Science & Technology

BlackRock Science and Technology Trust II

BlackRock MuniYield Quality Fund Inc

If you’re looking to boost your portfolio’s income stream, look at CEFs yielding 7%+

These 10 Mysterious Funds Crush Stocks And Yield Up To 9.4%

Calamos Convertible And High Income Fund

Credit Suisse High Yield Bond Fund

Cohen & Steers Reit And Preferred Income Fund Inc

During the last few months, most closed-end funds have been hit hard. Moreover, their recovery had lagged the broader market, but more recently, they have been catching up.

5 Best CEFs To Buy This Month (June 2020)

Invesco CurrencyShares British Pound Sterling Trust

Each year, MoneyShow asks the nation’s leading financial newsletter advisors for their top recommendations for the coming year. In our Top Picks 2020 Report, several experts chose mutual funds and ETFs as their best idea for the new year.

Top 6 Mutual Funds And ETFs To Buy For 2020

Barings Global Short Duration High Yield Fund

MFS Special Value Trust

RENN Fund

The Month In Closed-End Funds: November 2019

Nuveen NASDAQ 100 Dynamic Overwrite Fund

Royce Micro-Cap Trust

For income investors, closed-end funds are an attractive class of asset with the premise of high distributions and reasonable total return.

5 Best CEFs To Buy For May 2019 (Income Series)

News for abrdn Life Sciences Investors ETF (HQL)